Dr. Dattatraya Manohar Shinkar
@msgpharma.org
Associate Professor, Department of Pharmaceutics
Gokhale education Society's Sir Dr. M. S. Gosavi College of Pharmaceutical Education and Research, Nashik 422005, Maharashtra, India.
EDUCATION
Ph.D. (Pharmaceutical Sciences), M. Pharm. (Pharmaceutics)
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmaceutical Science
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Dattatraya Shinkar, Prashant Pingale, Sahebrao Boraste, Raosaheb Ghegade, and Sunil Amrutkar
De Gruyter
Sachin Kothawade, Vishal Pande, Dattatraya Shinkar, Prashant Pingale, and Sahebrao Boraste
De Gruyter
Anand More, Simranjit Kaur, Muktika Tekade, Vipulata Yeole, Prashant L. Pingale, Dattatraya Shinkar, and Rakesh Kumar Tekade
Elsevier
Y. S. Chavan, D. M. Shinkar, S. S. Jadhav, S. S. Boraste, P. L. Pingale, and S. V. Amrutkar
Springer Science and Business Media LLC
Dattatraya M. Shinkar, Sunil V. Amrutkar, and Prashant L. Pingale
De Gruyter
D. M. Shinkar, A. N. Patil, and R. B. Saudagar
A and V Publications
The solubility behavior of drug remains one of the most challenging aspects in formulation development. Most NCE are poorly water soluble, drug not well absorbed after oral administration. Solid dispersion is an increasingly important approach to enhance dissolution rate and solubility of poorly water soluble drug. Sulfasalazine is derivative of mesalazine. Sulfasalazine and its metabolite 5-aminosalicylic acid (5-ASA) are poorly absorbed from gut so its main mode of action is believed to be inside the intestine. It exhibits slow GI absorption rate and inter individual variation of its bioavailability. Thus solubility enhancement and dissolution enhancement of sulfasalazine from its dosage form is an important issue for its in vivo bioavailability and therapeutic efficacy. It was planned to improve the solubility of sulfasalazine by using polymer like Gelucire50/13. Different ratio were employed as 1: 1, 1: 3, 1: 5 and Solid dispersion were prepared by Solvent evaporation method, Physical mixture and Kneading method. Preformulation study was done before going to formulation in that melting point, solubility and compatibility study was done. The prepared solid dispersion also evaluated for percentage yield, percent drug content. Solubility study was done in water. Solid dispersion also characterized by FTIR, DSC, PXRD. In-vitro dissolution study was done in pH6.8 phosphate buffer using USP dissolution test apparatus type II.
M.S. Alai, D.M. Shinkar, and R.B. Saudagar
A and V Publications
A gastro retentive dosage form will release the drug over an extended period in the stomach and upper gastrointestinal tract (GIT) thus enhancing the opportunity for absorption. Various approaches have been proposed to control the gastric residence of drug delivery system in the upper part of the GIT including floating drug delivery system. Formulation of Gastro-Retentive dosage forms (GRDFs) containing suitable drug candidate which would remain in stomach and/or upper part of GIT for prolonged period of time there by is maximizing the drug release at desired site within the time before GRDFs leave the stomach and or upper part of GIT. Oral route has been the adopted and most convenient route for the drug delivery. Floating dosage forms have been developed to float over GI fluids and to release the drug over a desired period of time. Floating drug delivery system also name as hydrodynamically balanced system (HBS). Bioadhesion can be defined as the process by which a natural or a synthetic polymer can adhere to a biological substrate. When the biological substrate is a mucosal layer then, the phenomenon is known as mucoadhesion.
D. M. Shinkar, A. S. Dhake, and C. M. Setty
Parenteral Drug Association, Inc.
Since the early 1980s the concept of mucoadhesion has gained considerable interest in pharmaceutical technology. The various advantages associated with these systems made buccal drug delivery as a novel route of drug administration. It prolongs the residence time of the dosage form at the site of application. These systems remain in close contact with the absorption tissue, the mucous membrane, and thus contribute to improved and/or better therapeutic performance of the drug and of both local and systemic effects. This review highlights the anatomy and structure of oral mucosa, mechanism and theories of mucoadhesion, factors affecting mucoadhesion, characteristics and properties of desired mucoadhesive polymers, various types of dosage forms, and general considerations in design of mucoadhesive buccal dosage forms, permeation enhancers, and evaluation methods. LAY ABSTRACT: Over the past few decades the mucoadhesive buccal drug delivery system has received a great deal of attention to develop mucoadhesive dosage forms to enable the prolonged retention at the site of action, providing a controlled release of drug for improved therapeutic outcome. Mucoadhesive drug delivery gives facility to include a permeation enhancer/enzyme inhibitor or pHmodifier in the formulation and versatility in designing as multidirectional or unidirectional release systems for local and systemic action. Local delivery to tissues of the oral cavity has a number of applications, including treatment of local conditions such as periodontal disease, bacterial and fungal infections, and aphthous stomatitis and vesiculo bullous diseases. For the treatment of chronic diseases, the mucoadhesive buccal drug delivery system allows easily accessibility and is generally well-accepted for administeringdrugs by systemic action.